Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586677 | 0.82 | L3MBTL1 (0.52) | L3MBTL1NAMPTNSD2CYP3A4DYRK1A | |
| Hydrochloric Acid SCHEMBL6969707 | 0.81 | L3MBTL1 (0.51) | L3MBTL1NAMPTNSD2CYP3A4DYRK1A | |
| SCHEMBL1585183 | 0.81 | STK17B (0.52) | L3MBTL1NAMPTCYP3A4DYRK1AMAPT | |
| SCHEMBL22828603 | 0.80 | SYK (0.42) | L3MBTL1NAMPTNSD2CYP3A4DYRK1A | |
| SCHEMBL16829208 | 0.79 | L3MBTL1 (0.48) | L3MBTL1NAMPTCYP3A4DYRK1AMAPT | |
| SCHEMBL8200759 | 0.79 | MAPKAPK2 (0.38) | L3MBTL1NAMPTNSD2KDM4ELMNA | |
| SCHEMBL21880312 | 0.79 | CA12 (0.53) | CYP3A4TDP1GAASTK17BSTK17A | |
| SCHEMBL6485195 | 0.78 | L3MBTL1 (0.47) | L3MBTL1NAMPTCYP3A4DYRK1AMAPT | |
| SCHEMBL22828610 | 0.78 | DYRK1A (0.44) | L3MBTL1NAMPTNSD2DYRK1ACTSS | |
| SCHEMBL19234753 | 0.77 | NAMPT (0.51) | L3MBTL1NAMPTCYP3A4DYRK1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023077129-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| CN-1198839-C | Novel dipeptide amidines as thrombin inhibitors | AIBET GMBH & CO KG (DE) | 2005-04-27 | — | — | CN | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| EP-0873356-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-28 | — | — | EP | disclosed |
| CN-1175953-A | Novel dipeptide amidines as thrombin inhibitors | BASF AG (DE) | 1998-03-11 | — | — | CN | disclosed |
| WO-1996025426-A9 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | — | 1997-06-12 | — | — | WO | disclosed |
| WO-1996025426-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | L3MBTL1 521/4885NAMPT 2398/4885NSD2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.